Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Patrick Murphy

Family Medicine Mobile, AL Medical Doctor

NPI 1316384936 CMS profile 1054828

101 Memorial Hospital Dr Ste 200, Mobile, AL 36608

Open in the dashboard

General payments

$13,208

922 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Patrick Murphy of Mobile, AL is reported in the CMS Open Payments database as having received $13,208 across 922 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Family Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,771 178
2024 General $2,836 203
2023 General $2,397 172
2022 General $2,050 150
2021 General $1,620 111
2020 General $528 34
2019 General $1,007 74

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Patrick Murphy
  • Family Medicine median
  • Middle half of Family Medicine
  • National median

In program year 2025, general payments to Patrick Murphy were reported at $2,771. Among 56,786 Family Medicine profiles paid that year, the median was $155 and the middle half received between $45 and $549.

Show as a table
Year Patrick Murphy Family Medicine median Middle half National median
2019 $1,007 $150 $41–$543 $163
2020 $528 $120 $32–$415 $114
2021 $1,620 $137 $35–$551 $132
2022 $2,050 $137 $37–$512 $149
2023 $2,397 $149 $42–$545 $160
2024 $2,836 $156 $44–$560 $164
2025 $2,771 $155 $45–$549 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $2,523 191 payments
  2. Novo Nordisk Inc $1,398 113 payments
  3. Amgen Inc. $1,235 91 payments
  4. Salix Pharmaceuticals, a division of Bausch Health US, LLC $1,091 80 payments
  5. Janssen Pharmaceuticals, Inc $966 68 payments
  6. AstraZeneca Pharmaceuticals LP $724 38 payments
  7. Bayer HealthCare Pharmaceuticals Inc. $688 37 payments
  8. Lilly USA, LLC $611 47 payments
  9. Pfizer Inc. $544 36 payments
  10. Astellas Pharma US Inc $364 24 payments
  11. Other $3,066 197 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $13,174 919 payments
  2. Education $35 3 payments
Products named General payments · program years 2019–2025
  1. VRAYLAR $874 63 payments
  2. XARELTO $841 60 payments
  3. Ozempic $833 64 payments
  4. TRULANCE $796 64 payments
  5. RYBELSUS $736 58 payments
  6. Kerendia $688 37 payments
  7. QULIPTA $621 42 payments
  8. UBRELVY $592 41 payments
  9. EVENITY $561 45 payments
  10. FARXIGA $545 26 payments
  11. Other $9,967 697 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 157 drugs

Part D claims

9,430

Median for Family Practice: 1,826

Drug cost

$912,461

Median for Family Practice: $120,094

Branded share of claims

20.8%

Median for Family Practice: 18.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 179 $195,607
Mounjaro Tirzepatide Brand 86 $96,570
Eliquis Apixaban Brand 86 $78,532
Rybelsus Semaglutide Brand 51 $74,804
Jardiance Empagliflozin Brand 69 $58,846
Linzess Linaclotide Brand 52 $43,394
Januvia Sitagliptin Phosphate Brand 34 $39,199
Xarelto Rivaroxaban Brand 34 $24,067
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 22 $23,295
Kerendia Finerenone Brand 13 $22,786

The 10 drugs with the highest cost, of 157 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 105,120 Part D prescribers listed as Family Practice; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 137 billing codes

Paid by Medicare

$167,978

Of which drugs: $48,327

Medicare patients

240

Average age 73

Services billed

8,108

117 women, 123 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 52%
Ischemic heart disease 40%
Diabetes 38%
Chronic kidney disease 36%
Heart failure 30%
Depression 30%
Atrial fibrillation 28%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for injection into muscle 90662 Office 25 25 $2,026
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 11 57 $30
Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg J3420 Office 11 20 $17

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 36 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Kerendia
$211 13 —
VRAYLAR
$193 — —
Wegovy
$183 — —
TRULANCE
$147 13 —
Veozah
$146 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 36 with Patron

Records

922 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Family Medicine in Alabama

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record